Daré Bioscience Announces Grant From The Bill & Melinda Gates Foundation Of $750,000 To Fund Activities Related To Bacteria-Based Live Biotherapeutic Product Development
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience, Inc. has received a $750,000 grant from the Bill & Melinda Gates Foundation to fund activities related to the development of bacteria-based live biotherapeutic products. This follows a previous grant of approximately $585,000 for the development of a hydrogel formulation. The new grant will support Daré's efforts to analyze the global bacterial biologic supply chain and identify potential CMO partners for manufacturing clinical and commercial supplies of these products. Daré's expertise in auditing and recommending manufacturers was a key factor in their selection for this project.
January 17, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daré Bioscience received a $750,000 grant from the Gates Foundation to support the development of bacteria-based biotherapeutic products, indicating continued progress and support in their women's health initiatives.
The additional grant from a reputable organization like the Gates Foundation not only provides financial support but also validates Daré Bioscience's work in the field of women's health. This news is likely to be viewed positively by investors, as it demonstrates both progress in their product development and confidence from an external philanthropic entity. The grant is specifically aimed at enhancing Daré's capabilities in identifying manufacturing partners, which is a critical step towards commercialization. Therefore, the short-term impact on the stock price is likely to be positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100